LINC02275: A Potential Drug Target and Biomarker (G100506085)

Target Name: LINC02275

NCBI ID: G100506085

LINC02275

Other Name(s): long intergenic non-protein coding RNA 2275 | Long intergenic non-protein coding RNA 2275

LINC02275: A Potential Drug Target and Biomarker

LINC02275 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene, which is involved in the development and maintenance of many diseases, including cancer. MDS cells are characterized by a lack of normal cell division and an increased ability to survive and proliferate uncontrollably. LINC02275 has been shown to play a critical role in the regulation of MDS cell growth and has been identified as a potential drug target.

In addition to its role in MDS cells, LINC02275 has also been shown to have potential as a biomarker for several diseases, including cancer. By using techniques such as RNA sequencing and bioinformatics analysis, researchers have identified several unique features of LINC02275 that may make it an attractive candidate for cancer diagnosis and treatment.

One of the key findings that has emerged from these studies is the role of LINC02275 in the regulation of the cell cycle. LINC02275 is a key regulator of the G1/S transition, which is a critical step in the cell cycle that helps to prepare cells for cell division. MDS cells have a limited ability to divide and an increased sensitivity to external stress, which makes them more susceptible to cancer. LINC02275 has been shown to play a critical role in regulating the cell cycle and may be a potential drug target for cancer treatment.

Another finding that has emerged from these studies is the role of LINC02275 in the regulation of apoptosis, or programmed cell death. MDS cells have a high sensitivity to apoptosis and are often able to survive even in the presence of toxins that are designed to induce cell death. LINC02275 has been shown to play a critical role in regulating apoptosis in MDS cells and may be a potential drug target for cancer treatment.

In addition to its role in cell cycle and apoptosis, LINC02275 has also been shown to play a critical role in the regulation of stem cell maintenance. MDS cells are characterized by a limited ability to self-renew and differentiate, which makes them difficult to use for cancer treatment. LINC02275 has been shown to play a critical role in regulating stem cell maintenance and may be a potential drug target for cancer treatment.

Overall, LINC02275 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its role in the regulation of the cell cycle, apoptosis, and stem cell maintenance makes it a promising candidate for cancer treatment. Further research is needed to fully understand the potential of LINC02275 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2275

The "LINC02275 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02275 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets